Direct costs of glaucoma: Relationship between cost and severity of the disease

Real, Juan Pablo; Lafuente, M C; Palma, Santiago Daniel; Tártara, Luis Ignacio

doi:10.1177/1742395318803660

Cited by 14 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Existing studies evaluating the economic burden by disease stage conclude that direct medical costs increase with increasing disease severity [ 8 , 15 , 16 ]. A US claims-based analysis reported that patients with severe POAG had higher eye-related outpatient costs than patients with moderate and mild POAG (median, $639 vs. $546 vs. $476, respectively; P < 0.0001) as well as higher glaucoma-related pharmacy costs (median, $493 vs. $244 vs. $139, respectively; P < 0.0001) [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Association of systemic inflammation indices with visual field loss progression in patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches

Qiu

et al. 2021

EPMA Journal

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Association of systemic inflammation indices with visual field loss progression in patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches

Qiu

et al. 2021

EPMA Journal

View full text Add to dashboard Cite

“…Available studies depending on the economic development of the countries indicate annual direct medical costs of 45-809 euros. [5,12,13,15,27] The burden of direct medical costs on the monthly personal income is significantly higher in patients with advanced clinical stage, who receive low monthly personal income (One Way ANOVA: Av = 6.38; p = 0.0001).…”

Section: Discussionmentioning

confidence: 99%

“…[9] Surgical treatment performed at an early clinical stage prevents the progression of POAG and has lower or identical direct medical treatment costs compared to pharmacotherapy. [10] Direct medical costs for treatment increase as the disease severity progresses [11,12,13], but stagnate or decrease over time [14,15].…”

Section: Introductionmentioning

confidence: 99%

Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity

et al. 2022

View full text Add to dashboard Cite

Introduction/Objective. POAG treatment should be individually tailored to the disease severity and type, effectiveness and secondary side effects of the medications used. This research aimed to assess the direct medical costs and the cost effectiveness associated with pharmacotherapy in visually impaired people with primary open-angle glaucoma according to disease severity. Methods. This scientific study is designed as an observational cross-sectional study with a quantitative analytical approach and was conducted in the period from July 2020 to June 2021 on the territory of North Macedonia. The study included 157 patients with binocular POAG in the early, moderate and advanced clinical stage, up to the age of 67, with changes in visual acuity and work ability. During the assessment of the effects of pharmacotherapy were analyzed the types, mutual correlations and effectiveness of the most commonly prescribed antiglaucomatous medications and the cost benefit from their administration. Direct medical costs are calculated according to disease severity in the last 12 months using real-time data of public interest. Results. The beta blockers due to their affordable price and availability are the dominant option with high-cost benefit for primary treatment of POAG. Antiglaucoma medications and diagnostic procedures are major components of direct medical treatment costs. Conclusion. Pharmacotherapy is the dominant alternative compared to other types of treatment because it is safer and is associated with greater effictiveness and lower direct medical costs.

show abstract

“…The existing literature of the economic impact of poor adherence to glaucoma medication is limited 27. However, there is an indication that healthcare costs for patients with glaucoma increase with disease severity, and therefore, adequate management of glaucoma treatment is needed to effectively delay disease progression and thus reduce the economic burden of glaucoma 18 28 29…”

Section: Introductionmentioning

confidence: 99%

Predictors and long-term patterns of medication adherence to glaucoma treatment in Denmark—an observational registry study of 30 100 Danish patients with glaucoma

Kolko,

Faergemann Hansen,

G Dal

et al. 2024

BMJ Open Ophth

View full text Add to dashboard Cite

BackgroundSelf-treatment with glaucoma medication (eye drops) has been associated with adherence challenges. Poor adherence results in worse outcomes in terms of visual field loss.ObjectiveTo investigate patterns in medication adherence among Danish patients with glaucoma in relation to selected predictors of adherence, long-term adherence patterns, and long-term societal economic consequences of poor adherence.Methods and analysisThis register-based study included 30 100 glaucoma patients followed for 10 years between 2000 and 2018. Glaucoma was identified from the Danish national registers by diagnosis of Open Angle Glaucoma and/or by redeemed prescriptions of glaucoma medication. Logistic regression models were applied to estimate patient characteristics related to medical adherence. Diagnosis-related group fees were applied to estimate healthcare costs.ResultsHigh adherence in the first year(s) of treatment was less likely among men (ORfirst year: 0.78, 95% CI: 0.75 to 0.82), younger individuals and among those with a positive Charlson Comorbidity Index (CCI) score (ORfirst year/CCI≥3: 0.71, 95% CI: 0.63 to 0.80). Adherence in the first year and in the first two years was associated with adherence in the fifth (ORfirst year: 4.55, 95% CI: 4.30 to 4.82/ORfirst two years: 6.47, 95% CI: 6.10 to 6.86) as with adherence in the 10th year with slightly lower estimates. Being medical adherent was related to higher costs related to glaucoma medication after 5 and 10 years comparing with poor adherence, whereas poor adherence was associated with a marked increase in long-term costs for hospital contacts.ConclusionIncreasing age, female sex and low comorbidity score are correlated with better adherence to glaucoma treatment. Adherence in the first years of treatment may be a good predictor for future adherence. In the long term, patients with poor adherence are overall more expensive to society in terms of hospital contacts.

show abstract

Direct costs of glaucoma: Relationship between cost and severity of the disease

Cited by 14 publications

References 12 publications

Association of systemic inflammation indices with visual field loss progression in patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches

Association of systemic inflammation indices with visual field loss progression in patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches

Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity

Predictors and long-term patterns of medication adherence to glaucoma treatment in Denmark—an observational registry study of 30 100 Danish patients with glaucoma

Contact Info

Product

Resources

About